KindredBio Announces Filing of an Investigational New Animal Drug Application for KIND-002
/in Frontpage, Investor, News /by Russell RadefeldKIND-002 is expected to be a major new therapy for severe cutaneous diseases in dogs
SAN FRANCISCO, California. (February 3, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-002. KIND-002 is a potent molecule being developed for severe dermatological diseases in dogs.
News
- Kindred Biosciences to Present at Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences ConferenceMarch 2, 2021 - 8:38 am
- Kindred Biosciences Announces Submission of Parvovirus Monoclonal Antibody Data for Prophylactic IndicationFebruary 25, 2021 - 8:06 am
- Kindred Biosciences to Present at the BofA Securities Animal Health Virtual SummitFebruary 16, 2021 - 4:05 pm
Events
- Event: Kindred Biosciences to Present at the H.C. Wainwright Global Life Sciences ConferenceMarch 2, 2021 - 8:45 am
- Event: Kindred Biosciences to Present at the Barclays Global Healthcare ConferenceMarch 2, 2021 - 8:43 am
- Event: Kindred Biosciences to Present at the BofA Securities Animal Health Virtual SummitFebruary 16, 2021 - 4:12 pm
$4.78
0.39 (8.88%)

|
KindredBio proudly supports
Rabies Free Africa